Key terms
About EXEL
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EXEL news
Apr 11
4:42am ET
Exelixis downgraded to Equal Weight from Overweight at Barclays
Apr 10
12:25am ET
Buy Rating for Exelixis Amidst Positive Litigation Outlook and Cabozantinib Sales Performance
Apr 08
10:10pm ET
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)
Mar 29
4:33pm ET
Jacqueline Wright to Exit Exelixis Board in 2024
Mar 21
6:20am ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), IDEAYA Biosciences (IDYA) and Vor Biopharma (VOR)
Mar 11
11:13am ET
Biotech Alert: Searches spiking for these stocks today
Mar 04
12:20am ET
5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024
Feb 27
7:01pm ET
Exelixis exec Haley sells 47,020 common shares
Feb 26
3:11pm ET
Fly Insider: Exelixis, Akami among week’s notable insider trades
Feb 26
3:11pm ET
Fly Insider: Exelixis, Akami among week’s notable insider trades
Feb 26
7:17am ET
Truist Financial Keeps Their Buy Rating on Exelixis (EXEL)
Feb 23
7:48am ET
Maintaining Buy Rating on Exelixis Amid Patent Litigation and Strong Growth Prospects
Feb 16
6:27am ET
5 Best Mid-Cap Stocks to Buy Now, According to Analysts – February 2024
Feb 12
8:20am ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT)
Feb 11
9:10pm ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Envista Holdings (NVST)
Feb 09
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Feb 08
7:50am ET
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and Exelixis (EXEL)
Feb 08
1:02am ET
A New Cause for Concern: Exelixis Adds a New Environmental / Social Risk
Feb 08
12:30am ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Enanta Pharmaceuticals (ENTA) and Steris (STE)
Feb 07
9:25am ET
Exelixis Earns Buy Rating on Strong Financials and Positive Outlook
Feb 07
8:33am ET
Exelixis: Hold Rating Amidst Pending Litigation and Pipeline Developments
Feb 07
8:18am ET
Piper Sandler Remains a Buy on Exelixis (EXEL)
Feb 07
7:32am ET
RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL)
Feb 07
7:21am ET
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Exelixis (EXEL)
Feb 07
6:55am ET
Exelixis Receives Buy Rating from David Lebovitz on Strong Financials and Growth Prospects
Feb 07
5:31am ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), GE Healthcare Technologies Inc (GEHC) and Inspire Medical Systems (INSP)
Feb 07
5:31am ET
Buy Rating on Exelixis: Growth Prospects Amid Patent Rulings and Pipeline Developments
Feb 07
5:21am ET
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Impedimed Limited (OtherIPDQF)
Feb 07
2:45am ET
Sell Rating on Exelixis Inc.: Caution Amid Lackluster Growth and Uncertain Product Efficacy
Feb 06
4:18pm ET
Exelixis backs FY24 revenue view $1.825B-$1.925B, consensus $1.91B
Feb 06
4:17pm ET
Exelixis reports Q4 adjusted EPS 33c, consensus 21c
No recent press releases are available for EXEL
EXEL Financials
Key terms
Ad Feedback
EXEL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EXEL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range